These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22804784)

  • 1. Association between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients.
    Xu X; Han L; Duan L; Zhao Y; Yang H; Zhou B; Ma R; Yuan R; Zhou H; Liu Z
    Br J Clin Pharmacol; 2013 Feb; 75(2):516-23. PubMed ID: 22804784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients.
    Xu X; Ren H; Zhou B; Zhao Y; Yuan R; Ma R; Zhou H; Liu Z
    Lung Cancer; 2012 Aug; 77(2):438-42. PubMed ID: 22516052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients.
    Liu JY; Qian CY; Gao YF; Chen J; Zhou HH; Yin JY
    Chin J Cancer; 2017 Jan; 36(1):12. PubMed ID: 28093084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of genetic variations in DNA repair pathways with severe toxicities in NSCLC patients undergoing platinum-based chemotherapy.
    Zheng Y; Deng Z; Yin J; Wang S; Lu D; Wen X; Li X; Xiao D; Hu C; Chen X; Zhang W; Zhou H; Liu Z
    Int J Cancer; 2017 Dec; 141(11):2336-2347. PubMed ID: 28791697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.
    Xu X; Duan L; Zhou B; Ma R; Zhou H; Liu Z
    Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):786-92. PubMed ID: 22725681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.
    Powrózek T; Mlak R; Krawczyk P; Homa I; Ciesielka M; Kozioł P; Prendecka M; Milanowski J; Małecka-Massalska T
    Clin Transl Oncol; 2016 Feb; 18(2):125-31. PubMed ID: 26193985
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Li YQ; Zhang XY; Chen J; Yin JY; Li XP
    J Cancer Res Ther; 2018; 14(4):881-886. PubMed ID: 29970670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy.
    Fang C; Li XP; Gong WJ; Wu NY; Tang J; Yin JY; Li X; Zhang W; Zhou HH; Liu ZQ
    Clin Exp Pharmacol Physiol; 2017 Dec; 44 Suppl 1():21-29. PubMed ID: 27873337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy.
    Zhang L; Gao G; Li X; Ren S; Li A; Xu J; Zhang J; Zhou C
    PLoS One; 2012; 7(10):e48350. PubMed ID: 23118991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
    Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
    Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer.
    Chu TQ; Li R; Shao MH; Ye JY; Han BH
    Acta Pharmacol Sin; 2016 Nov; 37(11):1490-1498. PubMed ID: 27665847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
    He C; Duan Z; Li P; Xu Q; Yuan Y
    Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients.
    Yin JY; Meng XG; Qian CY; Li XP; Chen J; Zheng Y; Liu R; Zhou HH; Liu ZQ
    Acta Pharmacol Sin; 2015 Mar; 36(3):375-84. PubMed ID: 25732572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
    Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
    Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients.
    Xu X; Han L; Yang H; Duan L; Zhou B; Zhao Y; Qu J; Ma R; Zhou H; Liu Z
    Lung Cancer; 2013 Jan; 79(1):65-72. PubMed ID: 23127338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
    Shao M; Jin B; Niu Y; Ye J; Lu D; Han B
    Cell Biochem Biophys; 2014 Nov; 70(2):1227-37. PubMed ID: 24948471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer.
    Jia M; Zhu M; Wang M; Sun M; Qian J; Ding F; Chang J; Wei Q
    Oncotarget; 2016 May; 7(18):25291-303. PubMed ID: 26993769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.
    Zhang R; Jia M; Xu Y; Qian D; Wang M; Zhu M; Sun M; Chang J; Wei Q
    Int J Cancer; 2018 Mar; 142(6):1218-1229. PubMed ID: 29134637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
    Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.